Search research articles
Contact Us
Filters
Showing results (11-20 of 134) with videos related to
Page
of 14
Sort By:
Cancer
|
November 17, 2011
Mechanisms of resistance to vascular endothelial growth factor blockade
Shaad E Abdullah, Roman Perez-Soler
Oncology (Williston Park, N.Y.)
|
December 25, 2007
Clinical research of EGFR inhibitors and related dermatologic toxicities
Roman Perez-Soler, Eric Van Cutsem
Journal of Environmental Quality
|
October 27, 2020
Sources and priming of nitrous oxide production across a range of moisture contents in a soil with high organic matter
Carmen C Roman-Perez, Guillermo Hernandez-Ramirez
Current Oncology Reports
|
December 6, 2001
Tyrosine kinase inhibitors: a clinical perspective
Sanjay Goel, Sridhar Mani, Roman Perez-Soler
Journal of Experimental Therapeutics & Oncology
|
November 28, 2007
EGFR inhibitor-mediated apoptosis in solid tumors
Sanjay Goel, Manuel Hidalgo, Roman Perez-Soler
Drugs
|
March 1, 2014
Targeting angiogenesis in squamous non-small cell lung cancer
Bilal Piperdi, Amartej Merla, Roman Perez-Soler
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 4, 2008
RETRACTED: Tumor dependence on the EGFR signaling pathway expressed by the p-EGFR:p-AKT ratio predicts erlotinib sensitivity in human non-small cell lung cancer (NSCLC) cells expressing wild-type EGFR gene
Tianhong Li, Yi-He Ling, Roman Perez-Soler
Molecular Pharmacology
|
June 6, 2008
Erlotinib induces mitochondrial-mediated apoptosis in human H3255 non-small-cell lung cancer cells with epidermal growth factor receptorL858R mutation through mitochondrial oxidative phosphorylation-dependent activation of BAX and BAK
Yi-He Ling, Ruoping Lin, Roman Perez-Soler
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 1, 2007
Schedule-dependent interaction between the proteosome inhibitor bortezomib and the EGFR-TK inhibitor erlotinib in human non-small cell lung cancer cell lines
Bilal Piperdi, Yi-He Ling, Roman Perez-Soler
Methods in Molecular Biology (Clifton, N.J.)
|
October 9, 2015
Mechanobioreactors for Cartilage Tissue Engineering
Joanna F Weber, Roman Perez, Stephen D Waldman
Page
of 14
Search research articles
Search
Showing results (11-20 of 134) with videos related to
Sort By:
Page
of 14
Cancer
|
November 17, 2011
Mechanisms of resistance to vascular endothelial growth factor blockade
Shaad E Abdullah, Roman Perez-Soler
Oncology (Williston Park, N.Y.)
|
December 25, 2007
Clinical research of EGFR inhibitors and related dermatologic toxicities
Roman Perez-Soler, Eric Van Cutsem
Journal of Environmental Quality
|
October 27, 2020
Sources and priming of nitrous oxide production across a range of moisture contents in a soil with high organic matter
Carmen C Roman-Perez, Guillermo Hernandez-Ramirez
Current Oncology Reports
|
December 6, 2001
Tyrosine kinase inhibitors: a clinical perspective
Sanjay Goel, Sridhar Mani, Roman Perez-Soler
Journal of Experimental Therapeutics & Oncology
|
November 28, 2007
EGFR inhibitor-mediated apoptosis in solid tumors
Sanjay Goel, Manuel Hidalgo, Roman Perez-Soler
Drugs
|
March 1, 2014
Targeting angiogenesis in squamous non-small cell lung cancer
Bilal Piperdi, Amartej Merla, Roman Perez-Soler
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 4, 2008
RETRACTED: Tumor dependence on the EGFR signaling pathway expressed by the p-EGFR:p-AKT ratio predicts erlotinib sensitivity in human non-small cell lung cancer (NSCLC) cells expressing wild-type EGFR gene
Tianhong Li, Yi-He Ling, Roman Perez-Soler
Molecular Pharmacology
|
June 6, 2008
Erlotinib induces mitochondrial-mediated apoptosis in human H3255 non-small-cell lung cancer cells with epidermal growth factor receptorL858R mutation through mitochondrial oxidative phosphorylation-dependent activation of BAX and BAK
Yi-He Ling, Ruoping Lin, Roman Perez-Soler
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 1, 2007
Schedule-dependent interaction between the proteosome inhibitor bortezomib and the EGFR-TK inhibitor erlotinib in human non-small cell lung cancer cell lines
Bilal Piperdi, Yi-He Ling, Roman Perez-Soler
Methods in Molecular Biology (Clifton, N.J.)
|
October 9, 2015
Mechanobioreactors for Cartilage Tissue Engineering
Joanna F Weber, Roman Perez, Stephen D Waldman
Page
of 14